Payment overview · 2025
General Payments
$424.86
22 reported records · 11 companies
Healthcare provider profile · identity verified
Amanda Gail Hatcher, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BASSETT, VA · NPI 1679183115
Verified facts
What the public records show
CMS Open Payments records show Amanda Gail Hatcher, FNP received $424.86 in general payments during 2025 across 22 reported records.
Corcept Therapeutics accounted for 32.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $136.84 | 32.2% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $73.32 | 17.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.22 | 10.9% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$34.72 | 8.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.54 | 5.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.23 | 5.5% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $22.02 | 5.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.44 | 4.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.70 | 3.9% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $15.98 | 3.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.85 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $424.86 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $136.84 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $73.32 | 3 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $34.72 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.43 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 208 | 61 |
| Omeprazole | Omeprazole | 198 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 191 | 66 |
| Lisinopril | Lisinopril | 171 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 149 | 38 |
| Metformin Hcl | Metformin Hcl | 128 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 118 | 33 |
| Alprazolam | Alprazolam | 110 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 101 | 33 |
| Gabapentin | Gabapentin | 93 | 26 |
| Furosemide | Furosemide | 86 | 25 |
| Trulicity | Dulaglutide | 85 | 13 |
| Losartan Potassium | Losartan Potassium | 82 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 74 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 19 |
| Ibuprofen | Ibuprofen | 55 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 15 |
| Potassium Chloride | Potassium Chloride | 52 | 14 |
| Simvastatin | Simvastatin | 52 | 15 |
| Tramadol Hcl | Tramadol Hcl | 52 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 12 |
| Famotidine | Famotidine | 48 | 17 |
| Farxiga | Dapagliflozin Propanediol | 48 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 17 |
| Lovastatin | Lovastatin | 48 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 47 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 11 |
| Glimepiride | Glimepiride | 40 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 11 |
| Novolog Flexpen | Insulin Aspart | 36 | suppressed |
| Levemir Flexpen | Insulin Detemir | 33 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 33 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Ozempic | Semaglutide | 31 | 12 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 11 |
| Glipizide | Glipizide | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Eliquis | Apixaban | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 18 |
| Allopurinol | Allopurinol | 21 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | 11 |
| Nystatin | Nystatin | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $424.86 · 22 records | Corcept Therapeutics | CAPLYTA, FREESTYLE LIBRE 3, Kerendia, Korlym, OTEZLA, QULIPTA, REPATHA, SYNCHROMEDII, UBRELVY, VIVITROL, VRAYLAR, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error